2.13. Biochemical Analyses
thrombosis, heart failure
THROMBOSIS, HEART FAILURE
The following biochemical tests were performed: lipidogram (TC [total cholesterol], LDL-C [low-density lipoprotein cholesterol], HDL-C [high-density lipoprotein cholesterol], TGL [triglycerides]), pro-inflammatory marker (CRP), markers of thrombosis (Fibrinogen, Antithrombin III), markers of angiogenesis (VEGF, Ang-2), a marker of heart failure (NT-proBNP [N-terminal natriuretic propeptide type B]). The material for the study was collected in the morning, with a 14 h break from the last meal. Patients were instructed to limit their consumption of high-fat meals and alcohol, and to refrain from smoking and undertaking increased PA in the 2–3 days preceding the study. In order to determine the biochemical parameters, the patient’s blood was collected from the vein of the forearm after a 15 min rest. Particular methods of biochemical determinations included TC, LDL-C, HDL-C, TGL—enzymatic method, colourimetric method, determinations made on the Cobas Pro, C-503 analyser (Roche Diagnostics, Indianapolis, IN, USA); CRP—immunoturbidimetric method, determinations made on the Cobas Pro, C-503 analyser (Roche Diagnostics, Indianapolis, IN, USA); Fibrinogen—Clauss method, using the Multifibren reagent (Siemens Healthcare Diagnostic, Erlangen, Germany), determinations made on the AtellicaCoag 360 coagulation analyser (Siemens Healthcare Diagnostic, Erlangen, Germany); Antithrombin III—chromogenic method, using the INNOVANCE Antitrombin test (Simems Healthcare Diagnostic, Erlangen, Germany), determinations made on the AtellicaCoag 360 coagulation analyser (Siemens Healthcare Diagnostic, Erlangen, Germany); VEGF—xMAP Luminex method using the phenomenon of fluorescence (Luminex, Austin, TX, USA); Angiopoietin-2—Luminex xMAP fluorescence method (Luminex, Austin, TX, USA); and NT-proBNP—immunological method based on electrochemiluminescence (ECLIA), determinations carried out on the Cobas Pro, E-801 analyser (Roche Diagnostics, Indianapolis, IN, USA).